BUSINESS NEWS PRESS RELEASE

CONTACT INFORMATION:

NOTA Laboratories

Malcolm Kahn

201-615-5766

mkahn@notalabs.com

New_NOTA_laboratories-01-Small.jpg

FOR IMMEDIATE RELEASE

NOTA Laboratories developing Face Mask and Nose Pillow to treat viral and bacterial infections including flu & COVID-19

Ann Arbor, MI - October 30, 2020

NOTA Laboratories, a startup company spun out from the University of Michigan, is developing a single-use face mask insert, named VaBiNOx, to treat and/or protect individuals against viral and bacterial pathogens. This inexpensive insert, which uses a proprietary solid-phase nitric oxide (NO) generating chemical compound, is placed into the supplied face mask to generate on-demand NO when activated by the wearers exhaled breathe.

 

NO is a remarkable molecule produced by a variety of cells in the human body, including cells of our sinuses, lungs and blood vessels, to help prevent and fight off infection. Inhaled nitric oxide (iNO) is currently FDA approved to improve oxigenation in the lungs and has been shown to be effective against COVID-19, the annual flu and pneumonia. NO is one of the leading treatment candidates being studied around the world to further prove efficacy and dosing for treating COVID-19 infections. 

 

In hospitals, iNO treatment uses tanks of nitric oxide gas that is very expensive and not practical for use by ambulatory patients or the general public. The NOTA VaBiNOx would be used by a person for several hours a day over multiple days to kill infections in the early stage before they reach the lungs and overwhelm the body’s natural immune response. Dr. Mark Meyerhoff, Professor of Chemistry at the University of Michigan and Chief Technology Officer of NOTA, believes that '"...NO has been shown to have broad utility to fight an array of sinus and respiratory infections and is an effective broad-spectrum antiviral and antibacterial agent. VaBiNOx would allow physicians to prescribe a solution that should cost under $20 and be usable at home or on the go.”

 

NOTA has successfully completed two clinical trials and is in the process of applying for an EUA for COVID-19 treatment.